ASCO 2014 – Colorectal and Head & Neck Cancer

Chemoradiation or Cetuximab/Radiation Versus Induction Chemotherapy Followed by Chemoradiation in Locally Advanced SCCHN
ASCO 2014 – Colorectal and Head & Neck Cancer
Platinum-based chemoradiation therapy (CRT) is the current standard treatment for locally advanced SCCHN, and induction docetaxel/cisplatin/5-fluorouracil (TPF) is superior to cisplatin/5-fluorouracil alone, but it has not been tested when added to concomitant therapy. Read More ›
The E1308 Trial: Reduced-Dose IMRT in HPV-Associated OPSCC After Induction Chemotherapy
ASCO 2014 – Colorectal and Head & Neck Cancer
In the E2399 trial, HPV+ patients with oropharyngeal squamous cell carcinoma (OPSCC) attained 2-year overall survival (OS) of 95% and progression-free survival (PFS) of 86% when treated with induction chemotherapy (IC) and 70 Gy chemoradiation. Read More ›
RTOG 0522: The KRAS Variant and Response to Cetuximab
ASCO 2014 – Colorectal and Head & Neck Cancer
In many cancers, KRAS mutations can predict cancer risk, unique cancer biology, and response to certain therapeutic agents. RTOG 0522 was a phase 3 trial of cisplatin/radiation ± cetuximab for patients with locally advanced SCCHN, evaluating whether KRAS mutation status would predict the response to cetuximab in these patients (Weidhaas JB, et al. ASCO 2014. Abstract 6000). Read More ›

Page 1 of 3


© Amplity, Inc. All Rights Reserved. Privacy Policy